J. Brandt

发表

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

H. Zeidler, W. Golder, A. Krause, 2002, The Lancet.

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

M. Dougados, D. M. van der Heijde, R. Landewé, 2009, Annals of the rheumatic diseases.

Conventional treatments for ankylosing spondylitis

M. Dougados, S. van der Linden, B. Dijkmans, 2002, Annals of the rheumatic diseases.

Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.

A. Thiel, J. Braun, J. Brandt, 2003, Arthritis and rheumatism.

Up regulation of the production of tumour necrosis factor α and interferon γ by T cells in ankylosing spondylitis during treatment with etanercept

A. Thiel, J. Braun, J. Brandt, 2003 .

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis

S. van der Linden, D. M. van der Heijde, A. Boonen, 2005, Annals of the rheumatic diseases.

Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes

J. Braun, J. Brandt, J. Listing, 2007, Annals of the rheumatic diseases.

Rheumatic manifestations of lymphoproliferative disorders.

J. Braun, J. Brandt, U. Kiltz, 2007, Clinical and experimental rheumatology.

Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging

D. M. van der Heijde, R. Landewé, J. Braun, 2004, Annals of the rheumatic diseases.

Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging ( MRI ) – a comparison between contrast enhanced T 1 and short-tau inversion recovery ( STIR ) sequences

D. M. van der Heijde, R. Landewé, D. V. D. Heijde, 2005 .

Anti-TNF-α agents in the treatment of psoriatic arthritis

J. Braun, J. Brandt, 2006 .

Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept.

A. Thiel, J. Braun, J. Brandt, 2003, Annals of the rheumatic diseases.

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis

M. Dougados, D. M. van der Heijde, A. Boonen, 2019, Annals of the rheumatic diseases.

Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.

J. Braun, J. Brandt, J. Sieper, 2002, The Journal of rheumatology.

Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide

J. Brandt, W. Gross, C. Metzler, 2005, Annals of the rheumatic diseases.

Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.

Matthias Schneider, G. Burmester, H. Zeidler, 2007, The Journal of rheumatology.

Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: first clinical and laboratory experiences

Andreas Radbruch, A. Thiel, P. Wu, 2000, Annals of the rheumatic diseases.

Impact of anti-tumour necrosis factor α treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis

J. Braun, J. Brandt, J. Listing, 2004, Annals of the rheumatic diseases.

Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography

M. Dougados, D. M. van der Heijde, R. Landewé, 2013, Annals of the rheumatic diseases.

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab

J. Braun, J. Braun, J. Brandt, 2005, Arthritis Research & Therapy.

Pathogenetic role of Chlamydia, Yersinia and Borrelia in undifferentiated oligoarthritis.

G. Kingsley, J. Heesemann, J. Braun, 1992, The Journal of rheumatology.

The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general

M. Dougados, I. Olivieri, D. M. van der Heijde, 2010, Annals of the rheumatic diseases.

New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)

M. Dougados, B. Dijkmans, I. Olivieri, 2009, Annals of the rheumatic diseases.

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

J. Braun, J. Brandt, J. Listing, 2005, Arthritis research & therapy.

The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis

M. Dougados, D. M. van der Heijde, R. Landewé, 2009, Annals of the rheumatic diseases.

Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept

J. Braun, J. Brandt, J. Listing, 2005, Annals of the rheumatic diseases.

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

J. Braun, J. Brandt, J. Listing, 2005, Arthritis and rheumatism.

Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.

J. Braun, J. Brandt, J. Listing, 2005, Rheumatology.

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

H. Zeidler, G. Burmester, G. Burmester, 2005, Rheumatology.

Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.

J. Braun, J. Brandt, J. Listing, 2005, Rheumatology.

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

H. Zeidler, G. Burmester, G. Burmester, 2004, Annals of the rheumatic diseases.

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis

J. Braun, J. Brandt, J. Listing, 2004, Annals of the rheumatic diseases.

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.

D. M. van der Heijde, W. Golder, J. Braun, 2003, Arthritis and rheumatism.

Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthritides

J. Braun, J. Brandt, J. Sieper, 2005, Scandinavian journal of rheumatology.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges

Jan Brandt, Joachim Listing, Joachim Sieper, 2003, Current opinion in rheumatology.

Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.

H. Zeidler, G. Burmester, W. Golder, 2003, Arthritis and rheumatism.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

J. Braun, J. Brandt, J. Listing, 2003, Arthritis and rheumatism.

Treatment of active ankylosing spondylitis with pamidronate.

J. Braun, J. Brandt, J. Sieper, 2003, Rheumatology.

The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis.

J. Braun, J. Brandt, J. Zochling, 2005, Rheumatology.

Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems

D. M. van der Heijde, W. Golder, J. Braun, 2004, Annals of the rheumatic diseases.

Ankylosing spondylitis: new treatment modalities.

Jan Brandt, Helena Marzo-Ortega, Paul Emery, 2006, Best practice & research. Clinical rheumatology.

Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial

Andreas Krause, M. Baumgaertner, H. Zeidler, 2006, Annals of the rheumatic diseases.

[Effectiveness and safety of radium chloride in the treatment of ankylosing spondylitis. Results of an observational study].

J. Braun, J. Brandt, H. Stierle, 2006, Zeitschrift für Rheumatologie (Print).

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab

J. Braun, J. Brandt, J. Listing, 2005 .

Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy.

J. Häberle, J. Braun, J. Brandt, 1999, Rheumatology.

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.

J. Braun, W. Golder, J. Brandt, 2000, Arthritis and rheumatism.

New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti–tumor necrosis factor therapy

E. Veys, J. Braun, J. Brandt, 2001, Current opinion in rheumatology.

Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab.

J. Braun, J. Brandt, J. Listing, 2007, Rheumatology.

Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis

D. Heijde, J. Braun, J. Brandt, 2004, Annals of the rheumatic diseases.

OP0063 Three months results of a double-blind placebo controlled, phase-iii clinical trial of infliximab in active ankylosing spondylitis

H. Zeidler, G. Burmester, E. Gromnica-ihle, 2001 .

The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.

M. Dougados, P. Geusens, R. Landewé, 2011, Clinical and experimental rheumatology.

[A 46-year-old-patient with granulomatous prostatitis, arthralgia and haemorrhagic rhinitis].

J. Braun, J. Brandt, F. Heldmann, 2006, Deutsche medizinische Wochenschrift.

Anti-TNF-alpha agents in the treatment of psoriatic arthritis.

J. Braun, J. Brandt, 2006, Expert opinion on biological therapy.

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

M. Dougados, B. Dijkmans, I. Olivieri, 2009, Annals of the rheumatic diseases.

SpondyloArthritis international Society (ASAS) exercise by experts from the Assessment of patients with chronic back pain: a real patient New criteria for inflammatory back pain in

M. Dougados, B. Dijkmans, I. Olivieri, 2009 .

Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.

J. Braun, J. Brandt, J. Listing, 2004, The Journal of rheumatology.

Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years

J. Braun, J. Brandt, J. Listing, 2005, Arthritis Research & Therapy.

opinion including uncertainty appraisal (part I): classification of paper patients by expert classification criteria for axial spondyloarthritis SpondyloArthritis international Society The development of Assessment of

M. Dougados, B. Dijkmans, I. Olivieri, 2009 .

Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.

M. Dougados, R. Landewé, P. Emery, 2016, Clinical and experimental rheumatology.

Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis

M. Dougados, I. Olivieri, D. M. van der Heijde, 2016, Annals of the rheumatic diseases.

Infliximab treatment of severe ankylosing spondylitis: one-year followup.

J. Braun, J. Brandt, J. Sieper, 2001, Arthritis and rheumatism.

Increased frequency of Sjögren's syndrome in patients with spondyloarthropathy.

J. Braun, J. Brandt, J. Sieper, 1998, The Journal of rheumatology.

Current therapy with TNF blocking agents for ankylosing spondylitis and undifferentiated

J. Braun, J. Brandt, J. Sieper, 2004 .

THU0262 Sclerostin does not predict radiographic progression in patients on anti-tnf therapy – new results from the european ankylosing spondylitis (AS) infliximab cohort (EASIC)

M. Dougados, R. Landewé, P. Emery, 2013 .

Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- a antibody infliximab

J. Braun, J. Brandt, J. Listing, 2022 .

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

J. Braun, J. Brandt, J. Listing, 2005 .

[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].

J. Braun, J. Brandt, J. Listing, 2003, Zeitschrift fur Rheumatologie.

Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences

R. Landewé, J. Brandt, X. Baraliakos, 2005, Annals of the rheumatic diseases.

The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general

M. Dougados, I. Olivieri, R. Landewé, 2010, Annals of the rheumatic diseases.

Infliximab in the treatment of active and severe ankylosing spondylitis.

J. Braun, J. Brandt, J. Sieper, 2002, Clinical and experimental rheumatology.

Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-α antibody infliximab

J. Brandt, X. Baraliakos, M. Rudwaleit, 2005 .

Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis

M. Dougados, I. Olivieri, D. M. van der Heijde, 2016, Annals of the rheumatic diseases.